This research proposes that K2's superior adverse effect incidence is thanks, not less than partly, to unique JWH-018 metabolite exercise with the cannabinoid one receptor (CB1R), and suggests that metabolites of most medicines, but not the carboxy metabolite, retain in vitro As well as in vivo action at CB1Rs. Consequences https://mam-220109753.diowebhost.com/86220075/top-guidelines-of-synthetic-cannabinoids-eam2201